Trinity Biotech Plc Stock Current Liabilities
| TRIB Stock | USD 1.84 0.02 1.08% |
Trinity Biotech plc fundamentals help investors to digest information that contributes to Trinity Biotech's financial success or failures. It also enables traders to predict the movement of Trinity Stock. The fundamental analysis module provides a way to measure Trinity Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Trinity Biotech stock.
Trinity |
Trinity Biotech plc Company Current Liabilities Analysis
Trinity Biotech's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current Trinity Biotech Current Liabilities | 21 M |
Most of Trinity Biotech's fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Trinity Biotech plc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
In accordance with the recently published financial statements, Trinity Biotech plc has a Current Liabilities of 21 M. This is 98.8% lower than that of the Health Care Equipment & Supplies sector and 96.04% lower than that of the Health Care industry. The current liabilities for all United States stocks is 99.73% higher than that of the company.
Trinity Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Trinity Biotech's direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Trinity Biotech could also be used in its relative valuation, which is a method of valuing Trinity Biotech by comparing valuation metrics of similar companies.Trinity Biotech is currently under evaluation in current liabilities category among related companies.
Trinity Fundamentals
| Return On Equity | -19.13 | ||||
| Return On Asset | -0.13 | ||||
| Profit Margin | (0.42) % | ||||
| Operating Margin | (0.26) % | ||||
| Current Valuation | 335.56 M | ||||
| Shares Outstanding | 7.64 M | ||||
| Shares Owned By Insiders | 29.31 % | ||||
| Shares Owned By Institutions | 39.26 % | ||||
| Number Of Shares Shorted | 1.16 K | ||||
| Price To Earning | 31.00 X | ||||
| Price To Book | 5.11 X | ||||
| Price To Sales | 0.25 X | ||||
| Revenue | 56.83 M | ||||
| Gross Profit | 38.08 M | ||||
| EBITDA | (14.3 M) | ||||
| Net Income | (36.87 M) | ||||
| Cash And Equivalents | 10.01 M | ||||
| Cash Per Share | 0.41 X | ||||
| Total Debt | 54.86 M | ||||
| Current Ratio | 3.66 X | ||||
| Book Value Per Share | (3.12) X | ||||
| Cash Flow From Operations | (19.18 M) | ||||
| Short Ratio | 0.07 X | ||||
| Earnings Per Share | (4.96) X | ||||
| Price To Earnings To Growth | 1.30 X | ||||
| Target Price | 3.0 | ||||
| Number Of Employees | 18 | ||||
| Beta | 1.23 | ||||
| Market Capitalization | 14.18 M | ||||
| Total Asset | 59.44 M | ||||
| Retained Earnings | (48.64 M) | ||||
| Working Capital | 29.33 M | ||||
| Current Asset | 151 M | ||||
| Current Liabilities | 21 M | ||||
| Net Asset | 59.44 M |
About Trinity Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Trinity Biotech plc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Trinity Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Trinity Biotech plc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Trinity Biotech in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Trinity Biotech's short interest history, or implied volatility extrapolated from Trinity Biotech options trading.
Currently Active Assets on Macroaxis
When determining whether Trinity Biotech plc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Trinity Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Trinity Biotech Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Trinity Biotech Plc Stock:Check out Trinity Biotech Piotroski F Score and Trinity Biotech Altman Z Score analysis. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Complementary Tools for Trinity Stock analysis
When running Trinity Biotech's price analysis, check to measure Trinity Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Trinity Biotech is operating at the current time. Most of Trinity Biotech's value examination focuses on studying past and present price action to predict the probability of Trinity Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Trinity Biotech's price. Additionally, you may evaluate how the addition of Trinity Biotech to your portfolios can decrease your overall portfolio volatility.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |
Is Trinity Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Trinity Biotech. If investors know Trinity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Trinity Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Trinity Biotech plc is measured differently than its book value, which is the value of Trinity that is recorded on the company's balance sheet. Investors also form their own opinion of Trinity Biotech's value that differs from its market value or its book value, called intrinsic value, which is Trinity Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Trinity Biotech's market value can be influenced by many factors that don't directly affect Trinity Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Trinity Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Trinity Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Trinity Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.